TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02733965

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical Consultations
Description: The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T

Intervention type: OTHER
Group type: OTHER
Intervention: No Pharmaceutical Consultations
Study: NCT03068208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue-mediated photodynamic therapy
Description: The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
Study: NCT03517462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3Mg Tab
Description: ivermectin tablet
Study: NCT01297582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-6950
Description: 1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
Study: NCT00524615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 25 mg of spironolactone once daily or placebo for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spironolactone
Description: 25 mg of spironolactone once daily or placebo for 2 months
Study: NCT02713659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Literacy Promotion
Description: Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Literacy Promotion
Description: Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
Study: NCT04006392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia FX-635
Description: The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Laser
Description: Non-therapeutic output.
Study: NCT01067469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Bevacizumab
Description: 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
Study: NCT03344042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: 10mcg sufentanil
Study: NCT03646682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy with membrane peeling
Description: during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with membrane peeling
Description: during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
Study: NCT00860912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix
Description: surgical/reinforcing material
Study: NCT02840045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Musical stimulation during electroencephalography recording
Study: NCT00860912

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collagen Matrix
Description: surgical/reinforcing material
Study: NCT00951028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)
Description: 12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-steps adherence treatment
Description: Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-steps adherence treatment
Description: Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-steps adherence treatment
Description: Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
Study: NCT03263767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nuclear cells
Description: CD3+ cells if needed after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nuclear cells
Description: CD3+ cells if needed after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nuclear cells
Description: CD3+ cells if needed after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nuclear cells
Description: CD3+ cells if needed after transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin Injectable Product
Description: At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Study: NCT01067469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Bevacizumab
Description: 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
Study: NCT03530501

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Very low calorie ketogenic diet followed by low calorie diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Very low calorie ketogenic diet followed by low calorie diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Very low calorie ketogenic diet followed by low calorie diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic1
Description: B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic2
Description: B. animalis subsp. lactis and prebiotics fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic2
Description: B. animalis subsp. lactis and prebiotics fiber
Study: NCT02687698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
Study: NCT02693379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-VIA
Description: D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment.
Study: NCT01935414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ post-surgery for 48hrs then 4hrs/day until discharge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEDS post-surgery for 48hrs then 4hrs/day until discharge.
Study: NCT01727414

Intervention type: DRUG
Group type: OTHER
Intervention: OROS-Methylphenidate and placebo for inattentive type pts
Description: Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.

Intervention type: DRUG
Group type: OTHER
Intervention: OROS-Methylphenidate and placebo for combined type pts
Description: Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
Study: NCT03263767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin Injectable Product
Description: At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Study: NCT02830295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
Study: NCT03838692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: A daily oral dose at 30 mg.
Study: NCT01245296

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Timing of clamping the umbilical cord
Description: The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
Study: NCT01269502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temp Touch Diabetica Solutions inc.
Description: Daily measurement of skin temperature on feet for one year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspection
Description: Inspection of feet daily for one year
Study: NCT01338584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training 3 weeks before radical prostatectomy
Description: Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive preoperative pelvic floor muscle training
Description: Patient started to learn pelvic floor muscle 3 weeks before surgery
Study: NCT04485884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose A
Description: One time dose of IN-C005 dose A taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose B
Description: One time dose of IN-C005 dose B taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose C
Description: One time dose of IN-C005 dose C taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose D
Description: Oral administration of IN-C005 dose D once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose E
Description: Oral administration of IN-C005 dose E once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C005 dose F
Description: Oral administration of IN-C005 dose F once daily for 7 days.
Study: NCT03807284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A group psychosocial course
Description: A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
Study: NCT01731093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04384523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 20 mg/kg IV
Description: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 40 mg/kg IV
Description: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 80 mg/kg IV
Description: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 140 mg/kg IV
Description: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA 200 mg/kg IV
Description: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride)
Study: NCT01227005

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of blood products
Description: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of blood products
Description: The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
Study: NCT01683578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Variable Ventilation
Study: NCT02554981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% Ophthalmic Emulsion
Description: Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
Study: NCT02746185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-molecular-weight heparin
Description: dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
Study: NCT04919837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low vision aids
Description: the assisting devices fitting for low-vision patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low vision aids
Description: the assisting devices fitting for low-vision patients
Study: NCT00934908

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Green tea capsules taken twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active sugar pill.
Study: NCT04443166

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program
Description: a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program
Description: a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
Study: NCT03117179

Intervention type: OTHER
Group type: OTHER
Intervention: Discharge from patient after consultation in emergency department
Description: Discharge from patient after consultation in emergency department

Intervention type: OTHER
Group type: OTHER
Intervention: Discharge from patient after consultation in emergency department
Description: Discharge from patient after consultation in emergency department
Study: NCT03207802

Intervention type: DEVICE
Intervention: Discontinuation of using device
Description: Subject will be instructed to discontinuation of use of device
Study: NCT01587235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Description: Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other Statin
Description: Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
Study: NCT04785599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercices
Description: An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercices
Description: An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informative talk
Description: An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informative talk
Description: An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garment
Description: Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity.
Study: NCT01961648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rebreathing bag

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rebreathing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mask
Study: NCT03688568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib given orally as dose escalation treatment.
Study: NCT04794881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hours
Description: Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 48 hours
Description: Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
Study: NCT00951028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)
Description: 12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
Study: NCT02337907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: for blinding purposes
Study: NCT01647477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interview
Description: 25 minutes of semi directive interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: questionnaires to answer at baseline 45 minutes
Study: NCT02337907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: for blinding purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for blinding purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study: NCT02838056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection
Description: drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
Study: NCT02840045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-density electroencephalography
Description: Musical stimulation during electroencephalography recording

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Musical stimulation during electroencephalography recording